Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.
机构:[1]Emergency department, Zhongshan Hospital of traditional Chinese Medicine, No. 3 Kangxin road, west district, Zhongshan, Guangdong 528401, People’s Republic of China.[2]Pharmacology laboratory, Zhongshan Hospital of traditional Chinese Medicine, Zhongshan, Guangdong 528401, People’s Republic of China.[3]Clinical laboratory, Zhongshan Hospital of traditional Chinese Medicine, Zhongshan, Guangdong 528401, People’s Republic of China.[4]Prevention and health section, Zhongshan Hospital of traditional Chinese Medicine, Zhongshan, Guangdong 528401, People’s Republic of China.[5]Pediatrics, Zhongshan Hospital of traditional Chinese Medicine, Zhongshan, Guangdong 528401, People’s Republic of China.
Shen-ling-bai-zhu-san (SLBZS) regulates inflammation and gut microbiota which are associated with Streptococcus pneumoniae (Spn)-induced pneumonia. So, we studied the therapeutic effect of SLBZS and evaluated whether gut microbiota is associated with the effects of SLBZS in improving Spn-induced pneumonia.
Spn-induced pneumonia NIH mice were treated by SLBZS and cefixime. A CT scan was performed and Myeloperoxidase (MPO) activity in lung homogenates was determined using the MPO Colorimetric Assay Kit. Inflammation levels in lung homogenates were measured using ELISA. Bacterial load was coated on a TSAII sheep blood agar. Intestinal gut microbiota information was analyzed according to sequencing libraries.
SLBZS decreased bacterial load, reduced wet/dry weight ratio, inhibited myeloperoxidase activity, reduced the neutrophils count, and ameliorated lung injury. Furthermore, SLBZS inhibited interleukin (IL)-1β, IL-6, tumor necrosis factor-α, IL-2, IL-8, IL-12, and interferon-γ secretion and enhanced IL-10 secretion. These results suggest that SLBZS ameliorates lung injury in mice with Spn-induced pneumonia. Moreover, SLBZS reduced inflammatory cytokine levels in a concentration-dependent manner and increased gut microbiota abundance and diversity. After SLBZS treatment, bacteria such as Epsilonbacteraeota, Bacteroidetes, Actinobacteria, Proteobacteria, and Patescibacteria were significantly reduced, while Tenericutes and Firmicutes were significantly increased.
SLBZS ameliorates inflammation, lung injury, and gut microbiota in mice with S. pneumoniae-induced pneumonia.
基金:
This study was supported by Grants from Major Medical and Health of
Zhongshan Science and Technology Bureau (2016B1004).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
无
最新[2025]版:
大类|3 区医学
小类|2 区全科医学与补充医学
第一作者:
第一作者机构:[1]Emergency department, Zhongshan Hospital of traditional Chinese Medicine, No. 3 Kangxin road, west district, Zhongshan, Guangdong 528401, People’s Republic of China.
通讯作者:
推荐引用方式(GB/T 7714):
Jinli Feng,Weibo Dai,Cheng Zhang,et al.Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.[J].BMC complementary medicine and therapies.2020,20(1):159.doi:10.1186/s12906-020-02958-9.
APA:
Jinli Feng,Weibo Dai,Cheng Zhang,Houjun Chen,Ziliang Chen...&Yongmao Zhou.(2020).Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia..BMC complementary medicine and therapies,20,(1)
MLA:
Jinli Feng,et al."Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.".BMC complementary medicine and therapies 20..1(2020):159